LabMedica:
Non-small-cell lung cancer (NSCLC) represents the majority of lung cancer cases. Though targeted therapies have enhanced NSCLC survival rates recently, only around half of the patients receive timely biomarker testing for driver mutations to obtain targeted treatment. The barriers to this include expense, the absence of local testing facilities, a slow turnaround time for results, and the availability of insufficient or substandard tissue samples. Now, the early-access commercial launch of an NSCLC assay based on innovative High Definition PCR (HDPCR) technology could change all that.
